AKT1 and cancer: PI3K/Akt-ERK pathway is usually deemed as a major molecular target for cancer therapy due to its role in promoting MDR [27], and simultaneous inhibition of AKT and ERK often afforded satisfying growth inhibition on MDR cells [28].